Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.48
TEAR's Cash-to-Debt is ranked lower than
75% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. TEAR: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
TEAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: No Debt Max: No Debt
Current: 0.48
Equity-to-Asset -0.41
TEAR's Equity-to-Asset is ranked lower than
95% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TEAR: -0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
TEAR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.1  Med: 0.68 Max: 0.96
Current: -0.41
-1.1
0.96
Piotroski F-Score: 5
Altman Z-Score: -29.98
Beneish M-Score: -4.65
WACC vs ROIC
14.75%
-212.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -46.63
TEAR's Operating Margin % is ranked lower than
65% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TEAR: -46.63 )
Ranked among companies with meaningful Operating Margin % only.
TEAR' s Operating Margin % Range Over the Past 10 Years
Min: -46452.17  Med: -341.61 Max: -46.63
Current: -46.63
-46452.17
-46.63
Net Margin % -61.14
TEAR's Net Margin % is ranked lower than
67% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. TEAR: -61.14 )
Ranked among companies with meaningful Net Margin % only.
TEAR' s Net Margin % Range Over the Past 10 Years
Min: -75902.17  Med: -403.82 Max: -61.14
Current: -61.14
-75902.17
-61.14
ROA % -63.73
TEAR's ROA % is ranked lower than
81% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. TEAR: -63.73 )
Ranked among companies with meaningful ROA % only.
TEAR' s ROA % Range Over the Past 10 Years
Min: -132.11  Med: -75.36 Max: -37.9
Current: -63.73
-132.11
-37.9
ROC (Joel Greenblatt) % -234.12
TEAR's ROC (Joel Greenblatt) % is ranked lower than
70% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. TEAR: -234.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEAR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7452.46  Med: -3369.34 Max: -234.12
Current: -234.12
-7452.46
-234.12
3-Year Revenue Growth Rate 8.20
TEAR's 3-Year Revenue Growth Rate is ranked higher than
58% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TEAR: 8.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEAR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.2 Max: 69.7
Current: 8.2
0
69.7
3-Year EBITDA Growth Rate -19.80
TEAR's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. TEAR: -19.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEAR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -77.7  Med: -5.4 Max: 97.8
Current: -19.8
-77.7
97.8
3-Year EPS without NRI Growth Rate -23.00
TEAR's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. TEAR: -23.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEAR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.6  Med: 9.3 Max: 71.6
Current: -23
-78.6
71.6
GuruFocus has detected 2 Warning Signs with TearLab Corp $TEAR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEAR's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:GNWSF, OTCPK:EXDI, OTCBB:RPBIF, NAS:ROKA, OTCPK:ILIU, OTCPK:MDIT, OTCPK:MTST, OTCPK:TBIOD, NAS:BASI, OTCPK:CRRVF, OTCPK:DIGP, OTCPK:LEDIF, OTCPK:BTHCF, OTCPK:BZYR, NAS:ROSG, NAS:GENE, NAS:CBMX, OTCPK:MNLIF, OTCPK:MEDD, NAS:ATOS » details
Traded in other countries:TLB.Canada, OCVN.Germany,
Headquarter Location:USA
TearLab Corp is an in-vitro diagnostic company. The Company commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.

TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.

Top Ranked Articles about TearLab Corp

TearLab Receives Nasdaq Listing Extension
TearLab Osmolarity System Receives Brazilian Regulatory Approval
TearLab Corporation to Release First Quarter 2017 Financial Results on May 15, 2017
TearLab Announces CE Marking for Next-Generation System

SAN DIEGO, March 06, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) today announced that its next-generation in-vitro diagnostics testing platform is in conformity with all the applicable provisions of In Vitro Diagnostic Medical Devices Directive 98/79 EC enabling CE Marking of the device. CE Marking provides clearance in the European Union (EU) and European Free Trade Association (EFTA) member countries.
For the first time, the TearLab next-generation platform offers eye care professionals the ability to assess multiple biomarkers in human tears with a single nanoliter volume tear collection. The lab-on-a-chip platform provides quantitative measurements of tear proteins in a fully automated workflow that is consistent with the current TearLab Osmolarity System which many physicians have incorporated into their practice. This CE Marking provides regulatory clearance for both the device and the initial next-generation test card, capable of measuring both osmolarity and an inflammation biomarker, which together will help identify patients expected to respond to dry eye disease (DED) therapies. “TearLab’s next generation platform represents a breakthrough in providing improved ability to diagnose ocular diseases. With its multiplexing capability, the system will enable us to measure not only osmolarity, but many other proteins and biomarkers in the tear film that reflect ocular surface conditions such as inflammation and allergy,” said Eric Donnenfeld, MD, Clinical Professor of Ophthalmology New York University Medical Center. “We have used the current TearLab Osmolarity System to aid in the identification of DED patients in our practice and look forward to leveraging the capabilities of the new platform to improve our diagnostic accuracy and enhance the level of patient care we can deliver.” Seph Jensen, CEO of TearLab Corporation added, “CE Marking of our next-generation platform is a groundbreaking achievement for TearLab. This platform offers a safe, convenient and quantitative method to diagnose diseases using human tears. This platform will allow us to iterate various disposable tests aimed at diagnosing both eye related and other systemic diseases without the need to replace and develop hardware for each new test.” The Company also announced that it will move to quickly seek CE Marking for a second protein biomarker that will, when combined with osmolarity and the first inflammation biomarker, comprise the initial commercial multiplex test card on the new platform. The Company then plans to build a robust clinical data package and secure valuable feedback from global key opinion leaders in support of a 510(k) submission to the U.S. Food and Drug Administration, which is expected in the third quarter of 2017. To date, TearLab has placed over 5,000 devices worldwide and had more than 8 million tests performed on the TearLab Osmolarity System globally since the commercial launch in 2012. About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning the market for dry eye patients, the potential success in developing and commercializing the next generation testing system and the TearLab Osmolarity System, the ability to file and secure additional CE Marking and U.S. Food and Drug Administration approval for the next generation commercial test card and testing device. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact:
The Ruth Group
Lee Roth
Tel: 646-536-7012
[email protected]

Read more...
TearLab Announces 1-for-10 Reverse Split of Common Stock
SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) today announced that it will effect a 1-for-10 reverse stock split previously approved by the Company's stockholders at a special meeting held on February 23, 2017. The 1-for-10 reverse stock split will be effective as of the close of business on Friday, February 24, 2017, and the Company's common stock will begin trading on a split-adjusted basis on Monday, February 27, 2017 on both the Nasdaq Capital Market (Nasdaq) and the Toronto Stock Exchange (TSX).
The reverse stock split is intended to increase the price per share of the Company's common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq.  The trading symbol will remain TEAR on the Nasdaq and TLB on the TSX.  Proportional adjustments will be made to the conversion and exercise prices of the Company's outstanding warrants, convertible preferred stock and stock options, and to the number of shares issued and issuable under the Company's equity compensation plans. The number of authorized shares of the Company's common stock will be reduced to 9,500,000 shares.Information for StockholdersUpon the effectiveness of the reverse stock split, each ten shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share. The Company will not issue any fractional shares in connection with the reverse stock split.  Instead, a cash payment will automatically be made in lieu of any fractional shares.  The reverse stock split will not modify the rights or preferences of the common stock.The Company's transfer agent, Computershare Trust Company, N.A. (“Computershare”), will act as its exchange agent for the reverse stock split.  Computershare will provide stockholders of record holding certificates representing pre-split shares of the Company's common stock as of the effective date a letter of transmittal providing instructions for the exchange of shares.  Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.For questions about the exchange of pre-split shares, please contact Computershare at (800) 546-5141, within the United States, United States territories and Canada.  For assistance outside the United States, United States territories and Canada, please call 1 (781) 575-2765.Additional information pertaining to the reverse split, including on how to exchange shares, is contained in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on January 3, 2017.
About TearLab CorporationTearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include, among others, statements concerning whether the reverse stock split will increase the price of our common shares and whether we will be able to maintain our Nasdaq Capital Market Listing.  These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact:
The Ruth Group
Lee Roth
Tel: 646-536-7012
[email protected]

Read more...
TearLab Corporation to Report Fourth Quarter and Full-year 2016 Financial Results on March 9, 2017

SAN DIEGO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) will announce its fourth quarter and full-year 2016 financial results after market close on Thursday, March 9, 2017.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET on the same day to review the financial results and discuss recent business developments. Fourth Quarter 2016 Results Conference Call Details: Date: Thursday, March 9, 2017
Time: 4:30 p.m. ET
Live Call: 877-303-1593 (Pass Code: 74547130)
Replay: 855-859-2056 (Pass Code: 74547130) The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section. About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include, among others, statements concerning our future financial and operational performance. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including. but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact:
The Ruth Group
Lee Roth
Tel: 646-536-7012
[email protected]


Read more...
TearLab Provides Update on International Market Milestones

SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) announced today the achievement of several recent milestones in the global commercialization of the TearLab Osmolarity System, which provides an objective assessment to aid in the diagnosis and management of patients with dry eye disease.
Key Milestones Approval in the Republic of Korea by the Ministry of Health and WelfareRegulatory filing for approval in the Federative Republic of BrazilCommercial launch in the Republic of India The TearLab Osmolarity System was approved by the Ministry of Health and Welfare in the Republic of Korea as part of its New Medical Technology evaluation process. This approval allows Korean eye care professionals to begin offering this innovative test to their patients and enables TearLab to apply for public reimbursement of the osmolarity test.  With a population of over 50 million, Korea represents a new and significant developed market opportunity for the TearLab Osmolarity System. The Company plans to begin commercialization with the new approval in the first quarter of 2017 with its commercial partner, Wooree Technologies, who has an established presence in the Korean eye care market. The Company also submitted its application to the Agência Nacional de Vigilância Sanitária (ANVISA) for regulatory approval for the TearLab Osmolarity System in the Federative Republic of Brazil.  If approved by Brazilian regulatory authorities, the TearLab Osmolarity System can be commercialized in the largest market in Latin America with a population of over 200 million.  Based on average review times for similar classes of medical devices in Brazil, an approval is anticipated in the fourth quarter of 2017. Finally, the Company announced the commercial launch of the TearLab Osmolarity System in India with its commercial partner, My HealthSkape PVT Ltd.  Established in 1996, My HealthSkape is one of the largest distributors of ophthalmic equipment in India, supplying products to a broad range of hospitals and government organizations, with a particularly strong presence in the refractive surgery market.  The Company and My HealthSkape plan to exhibit to eye care professionals at the All India Ophthalmological Society meeting in mid-February 2017. Seph Jensen, CEO of TearLab Corporation said, "We are pleased to complete these major milestones for TearLab’s international business as we continue to increase our global footprint in key strategic markets. Due to their size and growing dry eye populations, these three markets represent significant opportunity for us to expand our business and continue toward our goal of making osmolarity testing a global standard of care in diagnosing dry eye disease.” The TearLab Osmolarity System is approved in more than 40 countries globally.  To date, TearLab has placed over 5,000 osmolarity testing devices worldwide, with more than 7 million tests performed globally since the first commercial launch of the TearLab Osmolarity System in 2012. About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include, among others, statements concerning whether we will receive reimbursement approval in Korea, whether we will receive approval of the TearLab Osmolarity System in Brazil as well as the timing of receiving such approval, the market for dry eye patients in Korea, Brazil and India, the potential success in commercializing the TearLab Osmolarity System in these markets, the future relationships with our commercial partners and the potential interest in the TearLab Osmolarity System in these three markets by eye care professionals and patients.  These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact:

The Ruth Group

Lee Roth

Tel: 646-536-7012

[email protected]

Read more...
TearLab Osmolarity System Receives Mexican Regulatory Approval

Planned Launch 1H 2017 through Newly-signed Distribution Partner Cyan Medica

SAN DIEGO, Jan. 25, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) announced today that it has received approval for the TearLab Osmolarity System from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico. This approval allows TearLab to begin selling the product to aid in the diagnosis of Dry Eye Disease (DED) in Mexico.
The TearLab Osmolarity System, which provides an objective assessment to diagnose and manage patients with DED by measuring the osmolarity of human tears, is expected to launch in the Mexican market in the first half of 2017. The Company has signed an exclusive distribution agreement with Cyan Medica, a prominent sales, marketing and distribution organization offering extensive knowledge, experience, relationships and proven success across the ophthalmic market in Mexico. Seph Jensen, CEO for TearLab Corporation said, "The COFEPRIS approval is a significant regulatory milestone for our Company as it further expands our global footprint, and gives us entry into one of the largest markets in which TearLab did not yet have a presence. We believe that there is a significant unmet need in the Mexican market for a reliable, objective tool to aid in the diagnosis of DED, which is supported by the interest in the approval of the TearLab Osmolarity System among the country’s eye care professionals.” DED is a highly prevalent condition in Latin America with an estimated 26 million people suffering from the disease.  As the second largest country in Latin America, Mexico represents a significant global market for DED diagnostics and treatments.  To date, TearLab has placed over 5,000 devices worldwide, with more than 6 million tests performed globally since the commercial launch of the TearLab Osmolarity System in 2012.  About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include, among others, statements concerning the  market for dry eye patients, the potential success in commercializing the TearLab Osmolarity System in Mexico by our commercial partner, the future relationships with commercial partners in Mexico and the potential interest in the TearLab Osmolarity System in Mexico by eye care professionals.  These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.


Investor Contact:

The Ruth Group

Lee Roth

Tel: 646-536-7012

[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.30
TEAR's PS Ratio is ranked higher than
97% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. TEAR: 0.30 )
Ranked among companies with meaningful PS Ratio only.
TEAR' s PS Ratio Range Over the Past 10 Years
Min: 0.29  Med: 18.71 Max: 503.52
Current: 0.3
0.29
503.52
EV-to-EBIT -1.80
TEAR's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: -1.80 )
Ranked among companies with meaningful EV-to-EBIT only.
TEAR' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.1  Med: -2.5 Max: -0.1
Current: -1.8
-27.1
-0.1
EV-to-EBITDA -2.37
TEAR's EV-to-EBITDA is ranked lower than
99.99% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. TEAR: -2.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.1  Med: -3.05 Max: -0.2
Current: -2.37
-30.1
-0.2
Current Ratio 2.88
TEAR's Current Ratio is ranked higher than
54% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. TEAR: 2.88 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s Current Ratio Range Over the Past 10 Years
Min: 0.19  Med: 2.39 Max: 20.62
Current: 2.88
0.19
20.62
Quick Ratio 2.39
TEAR's Quick Ratio is ranked higher than
53% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TEAR: 2.39 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.85 Max: 19.15
Current: 2.39
0.14
19.15
Days Inventory 100.67
TEAR's Days Inventory is ranked lower than
59% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. TEAR: 100.67 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s Days Inventory Range Over the Past 10 Years
Min: 61.57  Med: 135.98 Max: 219.56
Current: 100.67
61.57
219.56
Days Sales Outstanding 29.59
TEAR's Days Sales Outstanding is ranked higher than
89% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. TEAR: 29.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.59  Med: 62.63 Max: 1487.77
Current: 29.59
29.59
1487.77
Days Payable 81.90
TEAR's Days Payable is ranked higher than
67% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. TEAR: 81.90 )
Ranked among companies with meaningful Days Payable only.
TEAR' s Days Payable Range Over the Past 10 Years
Min: 28.27  Med: 115.69 Max: 705.37
Current: 81.9
28.27
705.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.20
TEAR's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. TEAR: -17.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEAR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -132.1  Med: -42.6 Max: -5.6
Current: -17.2
-132.1
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.02
TEAR's Price-to-Median-PS-Value is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TEAR: 0.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEAR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.06 Max: 22.71
Current: 0.02
0.02
22.71
Earnings Yield (Greenblatt) % -55.56
TEAR's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. TEAR: -55.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEAR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -727.8  Med: -39.75 Max: -3.7
Current: -55.56
-727.8
-3.7

More Statistics

Revenue (TTM) (Mil) $27.95
EPS (TTM) $ -3.31
Beta1.73
Short Percentage of Float7.62%
52-Week Range $1.55 - 9.00
Shares Outstanding (Mil)5.74

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 28 30
EPS ($) -2.86 -1.40
EPS without NRI ($) -2.86 -1.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 
Autonomous Driving Offers No Easy Path for Investors Jun 27 2017 

More From Other Websites
TearLab Receives Nasdaq Listing Extension Jun 21 2017
TearLab Corp. :TEAR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
Edited Transcript of TEAR earnings conference call or presentation 15-May-17 8:30pm GMT May 21 2017
TearLab reports 1Q loss May 15 2017
TearLab Corporation Reports First Quarter 2017 Financial Results May 15 2017
ETFs with exposure to TearLab Corp. : May 12, 2017 May 12 2017
TearLab Osmolarity System Receives Brazilian Regulatory Approval May 12 2017
TearLab Corporation to Release First Quarter 2017 Financial Results on May 15, 2017 May 01 2017
ETFs with exposure to TearLab Corp. : April 17, 2017 Apr 17 2017
Today's Research Reports on Stocks to Watch: TearLab and HTG Molecular Diagnostics Apr 04 2017
TearLab Corp. :TEAR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
TearLab Corp. :TEAR-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}